China Shineway Pharmaceutical Group Limited

HKSE 2877.HK

China Shineway Pharmaceutical Group Limited Price to Sales Ratio (P/S) on January 28, 2025: 1.26

China Shineway Pharmaceutical Group Limited Price to Sales Ratio (P/S) is 1.26 on January 28, 2025, a 1.16% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

China Shineway Pharmaceutical Group Limited 52-week high Price to Sales Ratio (P/S) is 11.14 on December 20, 2024, which is 782.69% above the current Price to Sales Ratio (P/S).
China Shineway Pharmaceutical Group Limited 52-week low Price to Sales Ratio (P/S) is 1.15 on February 05, 2024, which is -8.95% below the current Price to Sales Ratio (P/S).
China Shineway Pharmaceutical Group Limited average Price to Sales Ratio (P/S) for the last 52 weeks is 1.38.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

HKSE: 2877.HK

China Shineway Pharmaceutical Group Limited

CEO	Mr. Zhenjiang Li
IPO Date	Dec. 2, 2004
Location	China
Headquarters	No. 168 Shiluan Street
Employees	3,232
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Personal Care

Description

China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People's Republic of China and Hong Kong. The company offers modern Chinese medicines in the form of soft capsules, granules, and injections, as well as TCM Formula Granules in various therapeutic areas, including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. It also trades in agricultural products. The company was incorporated in 2004 and is headquartered in Shijiazhuang, the People's Republic of China. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited.

Key trends

Past 5 years